Pfizer Inc. (PFE)
| Market Cap | 147.14B |
| Revenue (ttm) | 63.83B |
| Net Income (ttm) | 10.75B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.89 |
| PE Ratio | 13.69 |
| Forward PE | 9.20 |
| Dividend | $1.72 (6.65%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 34,559,529 |
| Open | 25.90 |
| Previous Close | 25.74 |
| Day's Range | 25.76 - 26.11 |
| 52-Week Range | 20.92 - 30.43 |
| Beta | 0.44 |
| Analysts | Hold |
| Price Target | 29.36 (+13.45%) |
| Earnings Date | Aug 5, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.36, which is an increase of 13.45% from the latest price.
News
Pfizer: Shares Are Cheap, But They Could Get Even Cheaper Next Year
I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat. Cost-cutting measures have lifted EPS above expectations and could del...
Pfizer: Stagnation Is An Investment Opportunity
Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Despite recent stagnation, Pfizer has consistently maintained its dividend payout and remains undervalued. T...
Pfizer: This Is What Bulls Waited For
Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...
Pfizer experimental sickle cell drug fails phase 3 trial
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.
Pfizer's sickle cell drug fails main goal in late-stage trial
Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in patients 16 years of age and older.
July Readers Tagged 9 Ideal Dividend Dogs From 17 "Safer" Of 40 ReFa/Ro Mentions
Prior to July 31, 2025, my REaders mentioned 40 equities in their comments about my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about their ReFa/...
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many...
Pfizer's combination therapy improves survival in bladder cancer trial
Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in patients with muscle-invasive bladder cancer when administered before and ...
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the Phase 3 ...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting, signaling a successful turnaround is underway. Key drugs like Vyndaqel, Paxlovid, and Lobr...
Pfizer Q2: Dividends Speak Louder Than EPS
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other profit ...
Trump Tweets Trigger Stock Swings For Tesla, Boeing, Pfizer—And An Insider Trading Inquiry
When President Donald Trump hits "post" on Truth Social, Wall Street braces for impact.
Final Trade: PFE, SNV, PLTR & VLO
The final trades of the day with CNBC's Mike Santoli and the “Fast Money” traders.
Pfizer CEO talks lowering drug prices, tariffs, and earnings
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings resul...
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de Ge...
Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth i...
BMO Capital Markets' Evan Seigerman: I'm encouraged by Pfizer raising 2025 profit outlook
Evan David Seigerman, BMO Capital Markets managing director & healthcare head, joins CNBC's 'Squawk on the Street' to discuss outlooks on Pfizer.
MSFT & META CapEx Good for ORCL, HIMS Sells & PFE Rallies on Earnings
Marley Kayden takes investors through the morning's biggest movers, which included Hims & Hers (HIMS) sliding more than 10% after its earnings. Its revenue miss led to the selling action despite the c...
Dow Surges Over 100 Points; Pfizer Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday.
Buy Pfizer Stock At $24?
Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on...
Pfizer stock pops as big pharma giant delivers post-COVID comeback
Pfizer stock (PFE: NYSE) surged on Tuesday after the company delivered stronger-than-expected second-quarter results and lifted its profit outlook for the year. Revenue climbed 10% to $14.7 billion, t...
SPX Market Momentum, PLTR & PFE Earnings
Stocks are off to a strong start this week as investors shake off Friday's volatility. Kevin Green notes that Monday's action was technical in nature, with the S&P 500 (SPX) recapturing its 20-day mov...